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New (alternative) temozolomide regimens for the treatment of
glioma
Abstract
One barrier to successful treatment of malignant glioma is resistance to alkylating agents such as
temozolomide. The cytotoxic activity of temozolomide and other alkylating agents is believed to be
manifested largely by the formation of O-methylguanine DNA adducts. Consequently, the primary
mechanism of resistance to temozolomide is a function of the activity of the DNA repair enzyme
O-methylguanine DNA methyltransferase (MGMT). Fortuitously, MGMT is inactivated after each
reaction (ie, suicide enzyme). Therefore, if the rate of DNA alkylation were to outpace the rate of
MGMT protein synthesis, the enzyme could, in theory, be depleted. Several studies have shown that
prolonged exposure to temozolomide can deplete MGMT activity in blood cells, a process that could
potentially increase the antitumor activity of the drug. To date, however, there are limited data
demonstrating the depletion of MGMT activity in tumor tissue exposed to temozolomide. A variety of
dosing schedules that increase the duration of exposure and the cumulative dose of temozolomide are
currently being investigated for the treatment of glioma, with the goal of improving antitumor activity
and overcoming resistance. These alternative dosing regimens have been shown to deplete MGMT
activity in peripheral blood mononuclear cells, but the regimen that provides the best balance between
enhanced antitumor activity and acceptable hematologic toxicity has yet to be determined.
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Abstract 
 
One barrier to successful treatment of malignant glioma is resistance to alkylating agents such 
as temozolomide. The cytotoxic activity of temozolomide and other alkylating agents is believed 
to be manifested largely by the formation of O6-methylguanine DNA adducts. Consequently, the 
primary mechanism of resistance to temozolomide is a function of the activity of the DNA repair 
enzyme O6-methylguanine DNA methyltransferase (MGMT). Fortuitously, MGMT is inactivated 
after each reaction (ie, suicide enzyme). Therefore, if the rate of DNA alkylation were to outpace 
the rate of MGMT protein synthesis, the enzyme could, in theory, be depleted. Several studies 
have shown that prolonged exposure to temozolomide can deplete MGMT activity in blood cells, 
a process that could potentially increase the antitumor activity of the drug. To date, however, 
there are limited data demonstrating the depletion of MGMT activity in tumor tissue exposed to 
temozolomide. A variety of dosing schedules that increase the duration of exposure and the 
cumulative dose of temozolomide are currently being investigated for the treatment of glioma, 
with the goal of improving antitumor activity and overcoming resistance. These alternative 
dosing regimens have been shown to deplete MGMT activity in peripheral blood mononuclear 
cells, but the regimen that provides the best balance between enhanced antitumor activity and 
acceptable hematologic toxicity has yet to be determined.  
 
 
Keywords: MGMT, O6-methylguanine DNA methyltransferase, temozolomide, brain tumor, 
glioma 
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Introduction 
 
For decades, the mainstay of treatment for malignant glioma has been radiotherapy (RT) 
followed by alkylating agents such as the nitrosoureas, procarbazine, and, more recently, 
temozolomide. Initially temozolomide was approved for the treatment of recurrent high-grade 
glioma at a dose of 150 to 200 mg/m2/day for 5 days every 28-day cycle (ie, standard 5-day 
regimen).1-3 This clinical dosing regimen was determined based on preclinical studies conducted 
by Stevens and colleagues in the late 1980s showing schedule-dependent activity4 and phase I 
clinical studies conducted by Newlands and colleagues in the early 1990s.5,6 Subsequently, 
Brock et al demonstrated that a continuous daily regimen at a dose of 75 mg/m2/day was active 
and well tolerated for periods up to 6 or 7 weeks.7 This study began a very fruitful period of 
investigation into the clinical activity of a variety of alternative temozolomide dosing regimens.  
The cytotoxicity of temozolomide, like many other alkylating agents, is manifested 
primarily by methylation of the O6 position of guanine. Although these DNA adducts represent 
< 9% of the total DNA methylation events caused by temozolomide,8-10 O6-methylguanine 
induces DNA mismatch repair, which is unable to successfully repair the lesion, and the 
resulting double-strand breaks ultimately drive the cell to undergo apoptosis.11,12 In contrast, 
N7-methylguanine and N3-methyladenine, which constitute approximately 80% of the total 
methylation events, are readily repaired by the base excision repair pathway and are generally 
not cytotoxic.9,10 Therefore, generation of O6-methylguanine and a functional DNA mismatch 
repair pathway are both critical to the cytotoxic potential of temozolomide. The only cellular 
mechanism capable of repairing these adducts is the enzyme O6-methylguanine DNA 
methyltransferase (MGMT). Consequently, the cellular levels of MGMT can affect the 
cytotoxicity of temozolomide and other alkylating agents, and the amount of MGMT in tumor 
cells is often regulated by epigenetic silencing of the gene via hypermethylation of CpG islands 
within the MGMT gene promoter. Tumor cells with a methylated MGMT promoter produce less 
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MGMT protein. This is particularly relevant in light of recent studies showing that MGMT 
promoter methylation correlates with the clinical benefit of alkylating agents, particularly 
temozolomide.  
Recently, temozolomide was shown to significantly improve survival in patients with 
newly diagnosed glioblastoma (GBM) when administered concomitantly with RT and as 
maintenance therapy thereafter.3,13 A randomized, phase III trial jointly conducted by the 
European Organisation for Research and Treatment of Cancer (EORTC) and the National 
Cancer Institute of Canada (NCIC) Clinical Trials Group analyzed standard RT (60 Gy) alone 
compared with RT plus concomitant temozolomide (75 mg/m2/day × 6 weeks) followed by up to 
6 cycles of maintenance temozolomide using the standard 5-day schedule.3 Median survival 
was 12.1 months with RT alone versus 14.6 months for patients treated with RT plus 
temozolomide (p < 0.001), and 2-year survival was 27% in the temozolomide group compared 
with 10% in the control group.3 This trial also showed that methylation of the MGMT promoter 
correlated with improved survival in patients treated with RT plus temozolomide,14 suggesting 
that tumors presumably with low levels of MGMT protein caused by epigenetic gene silencing 
may respond better to temozolomide than tumors with high MGMT levels. These data also 
indicated that GBM with an unmethylated MGMT promoter may only show a marginal response 
to temozolomide. The retrospective MGMT promoter methylation analysis performed in the 
context of this large, randomized trial confirmed previous reports from several smaller studies 
and provided further evidence to support the hypothesis that MGMT promoter methylation 
status can profoundly affect sensitivity to alkylating agents.15,16 The growing body of evidence 
demonstrating the clinical importance of MGMT has generated considerable interest in the 
exploration of strategies to overcome MGMT-mediated resistance to alkylating agents. 
Research efforts have focused on either disabling the enzyme using inhibitors such as 
O6-benzylguanine (O6-BG) or depleting MGMT enzyme activity in tumor cells. 
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When MGMT repairs O6-methylguanine lesions, it transfers the alkyl group from guanine 
to a cysteine moiety in its active site, thereby repairing the DNA. In the process, however, 
MGMT is irreversibly inactivated such that new MGMT protein synthesis is required for recovery 
of MGMT activity.17,18 (Hegi ME, et al., unpublished manuscript) In theory, it may be possible to 
exploit this feature to overcome chemoresistance. If the number of O6-methylguanine DNA 
adducts formed were to exceed the synthesis of cellular MGMT, then MGMT activity could be 
depleted, thus increasing the cytotoxic potential of the alkylating agent. However, MGMT is also 
depleted in normal cells, particularly hematopoietic stem cells, resulting in hematologic toxicity. 
The therapeutic window is largest when tumor cells have lower levels of MGMT activity relative 
to normal tissue. This is often the case in tumor cells with a hypermethylated MGMT promoter, 
which effectively silences the gene.19,20 Epigenetic gene silencing of the MGMT promoter is 
found in 45% to 70% of high-grade gliomas.21-24 This reflects a general mechanism whereby 
tumor cells turn off many genes that might otherwise act to reduce mutations, to slow cell 
division, or to induce apoptosis in response to DNA damage or mutations. 
Unfortunately, the kinetics of MGMT depletion and recovery in tumor tissue is not well 
understood. Most studies have measured MGMT activity only in peripheral blood mononuclear 
cells (PBMC) taken from cancer patients receiving treatment with alkylating agents. However, it 
is not known whether MGMT activity in PBMC is a good surrogate for MGMT activity in tumor 
tissue. In fact, there is some evidence to suggest that depletion or inactivation of MGMT occurs 
more readily in PBMC and that MGMT activity in PBMC is not a reliable surrogate for MGMT 
activity in tumor tissue.25,26 This may reflect the fact that tumor cells are more metabolically 
active than PBMC and may synthesize new MGMT more rapidly. Depletion of MGMT activity 
was first described in patients with metastatic melanoma who were treated with temozolomide 
on the standard 5-day dosing schedule.27 This study revealed that MGMT levels in PBMC 
dropped within 4 hours of the initial dose to a median nadir of 53% below pretreatment levels, 
and continued dosing over subsequent days resulted in cumulative and progressive MGMT 
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depletion. In some patients recovery of MGMT protein levels to ~45% of pretreatment level 
occurred in only 48 hours after the last dose, suggesting that prolonged temozolomide exposure 
may effectively deplete MGMT in PBMC. To date, however, few studies have directly measured 
MGMT enzyme activity in tumor tissue.28,29 In one of these studies,28 patients with primary brain 
tumors were treated with O6-BG at various time points before surgery, and MGMT activity was 
measured in the resected tumor. The results showed that MGMT activity in primary brain tumors 
was nearly completely inhibited 6 hours after exposure to 120 mg/m2 O6-BG but was partially 
recovered 18 hours after exposure to O6-BG.28 This continues to be an area of controversy and 
active research. The key unanswered question is whether temozolomide dosing regimens that 
deliver a higher cumulative dose over a prolonged period of time can effectively deplete MGMT 
activity in the tumor and overcome chemoresistance. 
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Alternative Temozolomide Dosing Schedules 
 
Early clinical studies investigating compressed and extended dosing schedules suggested that 
continuous daily administration of temozolomide was more effective than a single dose.5,6 More 
frequent administration (eg, twice daily)6 yielded higher levels of O6-methylguanine DNA 
adducts, suggesting that the capacity of tumor cells to repair these adducts can be saturated. 
Unfortunately, hematologic toxicity was dose limiting with some schedules. For example, in a 
phase II trial in which 30 patients with metastatic melanoma received 5 doses of temozolomide 
(200 mg/m2) within 16 hours (total dose = 1,000 mg/m2), the majority (68%) of patients 
developed grade 3/4 thrombocytopenia, and 54% of patients developed grade 3/4 leukopenia,30 
which is rarely seen with the standard dosing regimen. Interestingly, pretreatment MGMT levels 
in PBMC correlated with the temozolomide dose intensity that patients were able to tolerate. 
Profound lymphopenia has also been reported in a retrospective analysis of melanoma patients 
who received temozolomide at a dose of 75 mg/m2/day for extended periods,31 and this may 
leave patients susceptible to Pneumocystis carinii pneumonia and other opportunistic infections, 
particularly when lymphocyte counts drop below 200 cells/µL. Patients in this study had 
received temozolomide either alone or in combination with thalidomide or interferon alfa, and 
60% of patients developed lymphopenia. There was a trend toward more frequent lymphopenia 
among patients who failed to take a 2-week drug holiday every 8-week cycle. These clinical 
experiences highlight the challenge, which is to find a dosing regimen that allows normal cells 
ample time to recover, thus avoiding dose-limiting hematologic toxicity, while maximizing 
depletion of MGMT and cytotoxic activity in the tumor.  
Since these early studies, a variety of alternative dosing schedules have been tested in 
clinical trials for the treatment of glioma. In general, these alternative regimens increase 
exposure to temozolomide over a 28-day cycle by approximately 2-fold compared with the 
standard 5-day regimen (Table 1). (Hegi ME, et al., unpublished manuscript) The extent to 
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which 2 of these alternative regimens were able to deplete MGMT was rigorously tested in a 
study reported by Tolcher et al.32 In this study, patients were treated with either an alternating 
weekly schedule (“7-days-on/7-days-off”) or for 21 consecutive days every 28-day cycle (21/28-
day schedule), and MGMT enzyme activity was assayed in PBMC collected at various time 
points during treatment. The results showed a time- and dose-dependent decrease in MGMT 
activity with both regimens. Continuous daily dosing for 7 days at 75 to 175 mg/m2/day reduced 
mean baseline MGMT activity by 72% on day 8 in a dose-dependent manner, but during the 7-
day rest period, MGMT activity recovered to 55% of baseline on day 15 (Fig. 1).32 The 21-day 
continuous schedule at a lower daily dose (85 to 125 mg/m2) produced a similar reduction in 
mean MGMT activity by day 14 that was sustained through day 21. MGMT activity was not 
measured on day 28, so it is not known to what extent MGMT activity recovered after 7 days of 
rest following 21 days of continuous dosing.  
This seminal study by Tolcher et al32 highlighted several aspects of MGMT depletion 
with temozolomide. Most important, depletion of MGMT activity was a nonlinear function of both 
the total cumulative dose and the area under the concentration time curve (best described by a 
maximum effect response model). At high daily doses, temozolomide appears to deplete MGMT 
levels more rapidly than at lower daily doses, but because of dose-limiting hematologic toxicity, 
high daily doses can only be tolerated for short periods of time. Temozolomide administration 
for 21 consecutive days at a low daily dose achieved a comparable cumulative dose and 
resulted in a comparable depletion of MGMT activity compared with the 7-days-on/7-days-off 
regimen at a higher daily dose. These data suggest that the 21-day schedule may provide more 
sustained depletion of MGMT in PBMC, whereas the 7-days-on/7-days-off regimen may allow 
for recovery of MGMT and potentially less hematologic toxicity.  
Although this study established an important benchmark for evaluating alternative 
regimens, it has some limitations.32 First and foremost, it is important to recognize that Tolcher 
and colleagues measured MGMT activity only in PBMC, not directly in tumor tissue. In addition, 
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no comparisons were made to the standard 5-day regimen. Therefore, it remains unknown 
whether these alternative regimens are more effective than the standard regimen in terms of 
MGMT depletion. Clearly, the schedule that most effectively depletes MGMT in tumor cells and 
strikes the best balance between antitumor activity and hematologic toxicity has yet to be 
defined.  
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Brain Tumor Trials Investigating Alternative Temozolomide Schedules 
 
Newly Diagnosed High-Grade Glioma 
All available published reports of alternative temozolomide dosing schedules that have been 
investigated in patients with newly diagnosed high-grade glioma are summarized in Table 2.33-43 
These studies have investigated alternative regimens in a variety of different settings within the 
context of initial therapy: either as maintenance therapy after concomitant RT plus 
temozolomide, as an alternative to the standard 75 mg/m2/day concomitant with RT, or in the 
neoadjuvant setting. Clearly, there still remain a number of key unanswered questions with 
respect to the optimal dosing schedule for temozolomide in the first-line setting. First, what is 
the optimal dose and schedule to combine with RT? Second, what benefit is derived from 
maintenance therapy? Third, what is the optimal dose and schedule to use as maintenance 
therapy?  
 
Optimal Dosing Schedule in Combination With RT 
Several studies have looked at different dosing schedules concomitant with RT. In the pivotal 
phase III trial in newly diagnosed GBM conducted by the EORTC/NCIC, 75 mg/m2/day was 
shown to be effective and well tolerated.3 Whether intermittent dosing or low metronomic doses 
(eg, 50 mg/m2/day) can improve efficacy remains unclear. Combs et al37,38 reported a series of 
53 patients with GBM who were treated with RT plus temozolomide (50 mg/m2/day), and no 
maintenance therapy was administered after RT. Surprisingly, median progression-free survival 
(PFS) was 8 months, and median overall survival was 19 months. This compares favorably to 
the results reported by Stupp et al3,13 both in the phase II and phase III trials, which included 
maintenance therapy after concomitant RT plus temozolomide. Although this was a single 
institution study, and the results may have been influenced by patient selection, it nevertheless 
raises important questions as to whether a low metronomic dose may be effective when given 
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concomitantly with RT and whether maintenance therapy provides added benefit. D’Agostino 
and colleagues39 have also investigated whether continuous daily administration of 
temozolomide during RT is necessary. They compared their results achieved with the standard 
dosing regimen (75 mg/m2 temozolomide 7 days per week × 6 weeks) to a historical control 
group treated at the same institution with 75 mg/m2/day × 5 days only during the first and last 
week of RT (total of 10 days). Median survival was 19 months and 21 months, respectively. 
However, continuous daily administration of temozolomide resulted in more severe toxicity (27% 
of patients had grade 3/4 adverse events compared with 3% in the historical control group). The 
authors concluded, based on the comparable survival outcomes and favorable safety profile, 
that intermittent administration of temozolomide during the first and last week of RT is 
effective.39 However, this would require prospective validation. Similarly, Zorlu et al43 reported 
using the 7-days-on/7-days-off regimen at a dose of either 100 or 150 mg/m2/day concomitant 
with conventional or hyperfractionated RT in 32 patients with GBM or anaplastic astrocytoma 
(AA), and patients received concomitant temozolomide only during the first and third week of 
RT. This regimen reduces the dose intensity of temozolomide delivered during RT compared 
with the 75 mg/m2 daily schedule, which delivers 3,150 mg/m2 over 42 consecutive days. 
Nevertheless, the median overall survival was 15 months, which compares favorably with the 
results achieved using the conventional regimen. These studies would have benefited from 
MGMT analysis, which would have not only provided important data for future patient selection 
but also would have provided an internal control to determine whether patient selection is an 
issue.  
 
Seven-Days-On/Seven-Days-Off Regimen 
The most widely investigated alternative dosing schedule in the first-line setting is the  
7-days-on/7-days-off regimen. In most studies the dose was 150 mg/m2/day administered on 
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days 1 to 7 and 15 to 21 of each 28-day cycle. Chinot et al36 examined the activity of this 
regimen in the neoadjuvant setting (up to 4 cycles before conventional RT) in 29 patients with 
inoperable, newly diagnosed GBM.36,44 Patients also received up to 4 cycles of temozolomide 
until disease progression as maintenance therapy after RT on the same schedule. In this 
setting, it is possible to directly assess the antitumor activity of the regimen, and MGMT 
expression was prospectively assessed by immunohistochemistry in 25 available tumor biopsy 
specimens. Patients in this study received a median of 3 cycles before RT, and best tumor 
response 1 month after completion of RT was partial response in 24% of patients and stable 
disease in 31% of patients. The median PFS was 3.8 months, and median survival was 
6 months. This schedule appeared to have good antitumor activity in this poor-prognosis 
population,45 and the response rate was comparable with that achieved with neoadjuvant 
therapy in similar patient populations using the standard 5-day schedule.46-48 Hematologic 
toxicity was manageable with dose reductions required in 6 (21%) patients because of grade 3 
or 4 thrombocytopenia and in 5 (17%) patients because of grade 3 or 4 neutropenia.36 Five 
patients also developed febrile interstitial pneumonitis associated with either profound 
lymphopenia or neutropenia. Analysis of MGMT revealed low expression (< 35% of tumor cells) 
in 11 patients and high expression (≥ 35% of tumor cells) in 14 patients. Notably, the response 
rate was 55% in patients with low MGMT expression and only 7% in patients with high MGMT 
expression (p = 0.004). Patients with low MGMT expression also had significantly longer PFS 
(5.5 versus 1.9 months, respectively; p = 0.009). Unfortunately, the results of this study did not 
support the conclusion that this regimen is more active than the standard 5-day regimen. As 
with most other studies reported to date, this study lacked a control arm for comparison. It is 
also important to note that the correlation between MGMT levels determined by 
immunohistochemistry and MGMT promotor methylation status has yet to be established.  
Clarke et al49 reported a randomized study investigating the 7-days-on/7-days-off dose-
dense regimen (150 mg/m2/day) as maintenance therapy for up to 6 cycles following standard 
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RT plus concomitant temozolomide (75 mg/m2/day) in patients (n = 67) with newly diagnosed 
GBM, and they compared this maintenance regimen with a metronomic daily dose of 50 
mg/m2/day. Patients in both arms also received oral cis-retinoic acid following completion of 
maintenance temozolomide. In the most recent report on this study, median overall survival has 
not been reached, but median PFS was longer for patients treated with the 7-days-on/7-days-off 
regimen compared with 50 mg/m2/day (6.6 versus 4.4 months).49 The most common grade 3/4 
hematologic toxicity was leukopenia (13%) and thrombocytopenia (6%). This study suggests 
that the higher daily dose and dose per cycle achieved with the 7-days-on/7-days-off regimen 
may be more effective than a low metronomic daily dose as maintenance therapy. Analysis of 
MGMT methylation status is planned.  
The largest clinical experience with the 7-days-on/7-days-off regimen in the first-line 
setting is the combined German-Swiss, randomized, phase III trial of the Neuro-oncology 
Working Group within the German Cancer Society (NOA-08).41 This trial is currently 
investigating the benefit of temozolomide (100 mg/m2/day, day 1 - 7 and 15 - 22) until treatment 
failure versus RT (60 Gy) alone as primary therapy for elderly patients (> 65 years old) with 
GBM or AA and will ultimately enroll 340 patients. Enrollment is ongoing (242 patients have 
been enrolled as of February 2008). The intriguing aspect of this study is that it compares dose-
dense temozolomide alone versus RT alone, but unfortunately, there is no comparison with the 
standard dosing regimen, and the benefit of this approach in younger patients will not be 
addressed.  
 
 
Optimal Maintenance Regimen 
With regard to the optimal maintenance regimen, there are as yet no data to suggest that 
alternative regimens are more effective at delaying disease progression or improving survival 
compared with the standard 5-day regimen. This question is currently being addressed in the 
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ongoing Radiation Therapy Oncology Group/EORTC trial in newly diagnosed GBM.50,51 This 
study is testing whether increasing the dose intensity of maintenance temozolomide improves 
survival compared with the standard regimen (Fig. 2).50,51 Following concomitant RT plus 
temozolomide, patients will be randomized to standard maintenance temozolomide therapy with 
150 to 200 mg/m2 x 5 days of every 28-day cycle or to 75 to 100 mg/m2 x 21 days of every 28-
day cycle (21/28-day regimen). Importantly, MGMT promoter methylation status will be available 
for all randomized patients. This study will hopefully provide definitive evidence to either support 
or refute the hypothesis that dose-dense temozolomide regimens can overcome resistance to 
alkylating agents.  
 
Recurrent Glioma 
All available published reports of alternative temozolomide dosing schedules that have been 
investigated in patients with recurrent glioma are summarized in Table 3.29,35,37,38,52-61 (Neyns B, 
et al., unpublished manuscript) In this setting, the 21/28-day and the 7-days-on/7-days-off 
regimens have been most widely studied. In most cases, the patients enrolled in these studies 
had not been previously treated with temozolomide, and in other studies, patients treated with 
standard RT plus temozolomide at initial diagnosis were rechallenged with temozolomide at 
recurrence. This is important given that patients with high-grade glioma are now commonly 
exposed to temozolomide at initial diagnosis and may develop resistance at the time of 
recurrence. Therefore, the question whether dose-dense temozolomide regimens can overcome 
resistance is even more relevant today in the recurrent disease setting.  
 
21/28-Day Regimen 
Several studies have tested the 21/28-day schedule at doses ranging from 75 to 
100 mg/m2/day. An Italian phase II cooperative group study reported by Brandes et al53,54 
investigated the safety and efficacy of this regimen at a dose of 75 mg/m2/day in 
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33 chemo-naive patients with recurrent GBM. The regimen was fairly well tolerated; only 18% of 
patients developed grade 3 lymphopenia, no patients developed grade 3/4 thrombocytopenia, 
and no Pneumocystis carinii pneumonia or other opportunistic infections were reported. 
However, lymphopenia was cumulative, and nearly all patients who received more than 9 cycles 
developed lymphopenia. They reported a 6-month PFS rate of 30%. Similarly, a small Belgian 
phase II study investigated the 21/28-day schedule at a dose of 100 mg/m2/day in 19 patients at 
first recurrence of AA or anaplastic oligoastrocytoma, and none of these patients had been 
previously treated with temozolomide. (Neyns B, et al., unpublished manuscript) These 
investigators observed a high incidence of cumulative grade 3/4 lymphopenia (100%), and 3 
patients developed profound and prolonged pancytopenia during the first cycle, suggesting that 
this dose may be too high for patients who are intrinsically susceptible because of low MGMT 
levels in normal tissue. (Neyns B, et al., unpublished manuscript)  Therefore, the authors 
suggested a starting dose of 75 mg/m2/day with escalation to 100 mg/m2/day if well tolerated; 
regular monitoring of WBC counts and prophylaxis against opportunistic infections also may be 
warranted. Although this was a small study, (Neyns B, et al., unpublished manuscript) 56% of 
patients were free of progression at 6 months, which is encouraging considering that none of 
the patients enrolled had loss of chromosome 1p or 19q in their tumor (a positive prognostic 
factor).  
Other studies have examined the activity of the 21/28-day regimen in patients previously 
exposed to temozolomide. For example, Jauch et al57 reported a retrospective analysis of 
45 patients with recurrent GBM (n = 23) or AA (n = 22) who had all progressed during or after 
completing first-line temozolomide. The majority were re-treated with the standard 5-day 
regimen, but 7 received the 7-days-on/7-days-off regimen at 150 mg/m2/day, 4 received the 
21/28-day regimen at 75 mg/m2/day, and 7 received continuous daily temozolomide at 
50 mg/m2/day. They reported that 8 of 12 patients who progressed during first-line 
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temozolomide and who were subsequently treated with 1 of these alternative regimens had an 
objective response or stable disease. Six-month PFS was 41% and 43% for patients with GBM 
and AA, respectively. This and other studies suggest that rechallenge with a dose-dense 
temozolomide regimen can result in good responses, but there have not been any direct 
prospective comparisons of different regimens in this setting.  
Seven-Days-On/Seven-Days-Off Regimen 
It has been suggested that intermittent dosing may reduce the frequency and severity of 
hematologic toxicity compared with more-extended dosing schedules such as the 21/28-day or 
extended daily schedules. Several studies have tested the 7-days-on/7-days-off regimen in the 
recurrent setting. Our experience with this regimen includes a phase II study in 21 patients with 
recurrent GBM61 and a larger phase II study in 90 patients with recurrent glioma (the majority of 
whom had not been previously treated with temozolomide).29 In both of these studies, we found 
that this regimen is well tolerated at a dose of 150 mg/m2/day. With appropriate dose reductions 
guided by WBC counts, there was no cumulative lymphopenia, and the overall incidence of 
grade 4 lymphopenia was 12%.29,61,62 Moreover, no patient developed an opportunistic 
infection.29 In the small phase II study in patients with recurrent GBM, this regimen produced a 
response rate of 9.5%, a 6-months PFS rate of 48%, and a median PFS of 21 weeks 
(~5 months).61 In our subsequent phase II trial in a larger group of patients that included GBM 
(n = 64), anaplastic glioma (n = 11), low-grade glioma (n = 9), and other brain tumors (n = 6), 
the same regimen was applied with individual dose adjustments according to hematologic 
toxicity.29 Grade 4 lymphopenia occurred in 12% of patients. Among patients with GBM, median 
PFS was 6 months, and the 6-month PFS rate was 44%. Analyses of MGMT promoter 
methylation were also performed on available tumor tissue from 36 patients with GBM; 17 
patients had a methylated promoter, and 19 had an unmethylated promoter.29 Median PFS was 
not significantly different between patients with a methylated or unmethylated MGMT promoter 
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(27 versus 19 weeks; p = 0.22). Moreover, median survival from diagnosis was similar in these 
2 subgroups. Although the sample size was small, this is the first evidence to suggest that a 
dose-dense temozolomide regimen may improve clinical outcomes in patients with an 
unmethylated MGMT promoter, potentially by depleting MGMT in tumor tissue. For comparison, 
among newly diagnosed GBM patients in the EORTC/NCIC trial who were treated with 
temozolomide, Hegi et al14 observed a median survival of 22 months for patients with a 
methylated MGMT promoter and 13 months for patients with an unmethylated promoter.  
The only study that directly compared the 7-days-on/7-days-off regimen with the 
standard 5-day regimen in the recurrent setting was reported by D’Amico et al.55 Unfortunately, 
this was a very small study involving only 20 patients with GBM who progressed after surgery 
and RT. The dose used in the 7-days-on/7-days-off regimen was initiated at 50 mg/m2/day and 
escalated up to 150 mg/m2/day, and the investigators reported that this was well tolerated. 
Median survival was 21 months for patients treated with the 7-days-on/7-days-off regimen 
versus 14 months for patients treated with the standard 5-day regimen.55 Although this was a 
small study, it suggests that the 7-days-on/7-days-off regimen may be more effective in this 
setting.  
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Discussion 
 
Resistance to alkylating agents remains a critical barrier to the effective treatment of malignant 
glioma. This has been most clearly demonstrated by studies showing that patients with an 
unmethylated MGMT promoter or higher levels of MGMT protein in their tumors are less likely to 
respond to alkylating agents and have shorter survival compared with patients with a methylated 
MGMT promoter or lower levels of MGMT protein. These clinical observations have spawned a 
concerted research effort to better understand the mechanisms of resistance to alkylating 
agents and to simultaneously design strategies to overcome chemoresistance in malignant 
glioma. In particular, the emergence of temozolomide as a highly effective agent for the 
treatment of high-grade glioma has provided opportunities to exploit the flexibility of this oral 
agent and to design dosing regimens with the potential to deplete MGMT and increase the 
cytotoxic activity of the drug. The depletion of MGMT by prolonged exposure to temozolomide 
appears to be a promising strategy to overcome resistance, and several alternative dose-dense 
temozolomide regimens have been shown to effectively deplete MGMT in PBMC. However, it 
remains unclear how effectively these regimens can deplete MGMT activity in tumor tissue, and 
dose-limiting hematologic toxicity remains an issue. A variety of alternative temozolomide 
dosing regimens have been investigated for the treatment of glioma in both the front-line and 
recurrent settings. These regimens appear to be effective and may improve clinical outcomes; 
however, there is a paucity of prospective studies comparing these alternative regimens with the 
standard 5-day regimen, and there is as yet little data to suggest that they can overcome 
MGMT-mediated resistance. Large-scale trials are under way that may provide some answers 
to a variety of unanswered questions.  
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TABLES 
Table 1. Alternative Temozolomide Dosing Schedules 
 
 
Regimen 
 
Daily dose, 
mg/m2
 
 
Schedule 
Dose intensity, 
mg/m2 per  
28-day cycle 
 
Relative dose 
intensity 
5/28 days 200 5 days every 28 days 1,000 1 
Daily 75 Daily × 6 to 7 weeks 2,100 2.1 
10/28 days 150 Day 1 to 5 and 15 to 19 
every 28 days 
1,500 1.5 
14/28 days 150 7 days on/7 days off 2,100 2.1 
21/28 days 100 21 days on/7 days off 2,100 2.1 
Reprinted with permission from Hegi ME, et al (unpublished manuscript). 
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Table 2. Clinical Studies of Alternative Temozolomide Dosing Regimens in Patients With Newly Diagnosed High-Grade Glioma 
First author (year) N Patient population Schedule 
Median PFS, 
months 
Median OS, 
months 
Stupp et al. (2005)3 573 Newly Dx GBM 
RT + TMZ (75 mg/m2) followed by 
150-200 mg/m2 days 1 to 5 q28d 
vs RT alone (60 Gy) 
6.9 
 
5.0 
14.6 
 
12.1 
Athanassiou et al. 
(2005)33 110 Newly Dx GBM 
RT + TMZ (75 mg/m2) followed by 
150 mg/m2 days 1 to 5, 15 to 19 q28d 
vs RT alone (60 Gy) 
10.8 
 
5.2 
13.4 
 
7.7 
Caroli et al. (2007)35  38 Newly Dx GBM After surgery and RT, 150 mg/m
2 on days 1 to 5, then  
75 mg/m2 on days 6-10 q28-day cycle 10 16 
Chinot et al. (2007)36  29 Inoperable, newly Dx GBM 
150 mg/m2 day 1-7 and 15-21 q28d as neoadjuvant tx before RT 
and maintenance after RT 3.8  6
Combs et al. (2005, 
2007)37,38  53 Newly Dx GBM 
RT + TMZ (50 mg/m2) concomitant 
no maintenance 8 19 
D’Agostino et al. 
(2007)39a  41 
newly Dx GBM (n=29) or 
AA (n=12) 
RT + TMZ (75 mg/m2 7d/w from 1st to last day of RT)a 
or RT + TMZ (75 mg/m2 5d/w 1st and last week of RT) 
NA 
19  
21 
Montemaggi et al. 
(2005)40  40 
Newly Dx  
high-grade 
glioma 
RT + TMZ (75 mg/m2) followed by 250 mg/m2 5/28 days 
NA 20 
NOA-0841 
(open)  
340 
planned 
Newly Dx  
GBM or AA  
> 65 years old 
100 mg/m2 day 1-7 and 15-21 q28d 
or RT alone  NA  NA
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Clarke et al. (2007)49  67 Newly Dx GBM 
RT + TMZ (75 mg/m2) followed by 
150 mg/m2 day 1-7 and 15-21 q28 days plus cis-retinoic acid 
or 50 mg/m2/day for 6 28-day cycles plus cis-retinoic acid 
 
6.6 
4.4 
NR 
Zorlu et al. (2005)43 
17 
 
15 
Newly Dx  
GBM or AA  
RT + TMZ (100 mg/m2/day) during week 1 and 3 of fractionated RT 
 
or RT + TMZ (150 mg/m2/day) during week 1 and 3 of fractionated 
RT 
NA   15
(all patients 
combined) 
PFS = Progression-free survival; OS = Overall survival; Dx = Diagnosed; GBM = Glioblastoma; RT = Radiotherapy; TMZ = Temozolomide; q28d = Every 28 days; tx = 
Treatment; AA = Anaplastic astrocytoma; d/w = Days per week; NA = Not available; NOA = Neuro-Oncology Working Group of the German Cancer Society; NR = Not 
reached. 
aThis trial compared these results with same-institution, historical results found with a less frequent administration schedule. 
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 1 
Table 3. Clinical Studies of Alternative Temozolomide Dosing Regimens in Patients With Recurrent Glioma 
First author (year) N Patient population Schedule 
Median PFS, 
months 
6-month  
PFS rate  
Median OS, 
months 
Berrocal et al. 
(2006)52  29 Glioma 85 mg/m
2 21/28 days 2 NA 6 
Brandes et al. 
(2005, 2006)53,54  33 GBM  75 mg/m
2 21/28 days NA 30% NA 
Caroli et al. (2007)35  30 GBM 150 mg/m
2 on days 1 to 5; 75 mg/m2 on days 6-10  
q28d 6 NA 14 
Combs et al. (2005, 
2007)37,38  17 
GBM, AA, astrocytoma, 
and gliosarcoma 
Re-irradiation RT concomitant with TMZ (50 mg/m2/d)  
14 pt also rec’d adjuvant TMZ NA   56% 39
D’Amico et al. 
(2006)55  
10 
 
10 
GBM 
50 mg/m2 day 1-7 and 15-21 q28d cycle 1 then 
escalation in 25 mg/m2 increments to 150 mg/m2
150 mg/m2 days 1-5/28 cycle 1,  
then 200 mg/m2
NA NA 
21 
 
14 
Donfrancesco et al. 
(2005)56  
17 
(pediatric) Neuroblastoma 180 or 215 mg/m
2 5/28 days 3.4 NA 8 
Jauch et al. (2007)57  45 GBM (n=23) AG (n=22) 
Rechallenged with one of following 
     150-200 mg/m2 5/28-day (n = 35)   
     150 mg/m2 day 1-7 q28d (n = 7) 
      75 mg/m2 21/28-day (n = 4) 
      50 mg/m2/day (n = 7) 
NA 
GBM 41% 
AG 43% 
NA 
First author (year) N Patient population Schedule 
Median PFS, 
months 
6-month 
PFS rate  
Median OS, 
months 
Khan et al. (2002)58  35 28 GBM, 3 AA, 2 AO, 2 oligodendroglioma 75 mg/m
2 42/70 days    2.5 NA 8.7
Neyns et al. 
(unpublished 
manuscript)  
19 AA & AO 100 mg/m2 21/28 days NA 56% 12.9 
Strik et al.  
(2007)59  
13 GBM (n=11) AA, AO 
1st-line: RT + 200 mg/m2  5/28 days TMZ 
2nd line: 8 of 13 pts switched dose-dense regimen  
(75-130 mg/m2 21/28 days TMZ) individually tailored to 
stay below target hematologic toxicity   
NA 
55% 
GBM 44% 
18 
Wen et al. (2005)60  29 Glioma 75 mg/m2 49/77 days > 16 NA NA 
Wick et al. (2007)29  90 
GBM (n=64) 
AG (n=11) 
Low-grade (n=9)  
Other (n=6) 
150 mg/m2/day days 1-7, 15-21 q28 days 6 GBM 44% 
9.5 
from  
progression 
Wick et al. (2004)61  21 Recurrent GBM 150 mg/m2 day 1-7 and 15-21 q28d 5 48% NA 
PFS = Progression-free survival; NA = Not available; OS = Overall survival; dx = Diagnosed; GBM = Glioblastoma; q28d = Every 28 days; AA = Anaplastic astrocytoma; 
RT = Radiotherapy; TMZ = Temozolomide; AG = Anaplastic glioma; tx = Treatment; AO = Anaplastic oligoastrocytoma. 
aThis trial compared these results with same institution, historical results found with a less frequent administration schedule. 
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FIGURE LEGENDS 
 
Fig 1. Levels of O6-methylguanine DNA methyltransferase (MGMT) enzyme activity in peripheral 
blood mononuclear cells at baseline and after treatment with temozolomide using the 7-days-
on/7-days-off schedule at doses ranging from 75 to 175 mg/m2/day (panel A) or the 21/28 day 
schedule at doses ranging from 85 to 125 mg/m2/day (panel B). Reprinted with permission from 
Tolcher et al.32  
 
Fig. 2 Study schema for the ongoing Radiation Therapy Oncology Group Intergroup trial.  
MGMT = O6-methylguanine-methyltransferase; RPA = Recursive partitioning analysis; RT = 
Radiotherapy; TMZ = Temozolomide. *Dosing will be initiated at 75 mg/m2 in cycle , with dose 
escalation to 100 mg/m2 in subsequent cycles if no dose-limiting hematologic toxicity occurs. 
Data from the National Cancer Institute51 and the European Organisation for Research and 
Treatment of Cancer.50 Reprinted with permission from Hegi ME, et al (unpublished 
manuscript). 
 
 
 
 
